Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3003 in Relapsed or Refractory Multiple Myeloma
NCT07336472Phase 2Recruiting
- Sponsor
- Fortvita Biologics
- Start
- Sep 2026
- Primary completion
- Jun 2027
- Modality
- Trispecific Antibodies, T-cell Engagers, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of IBI3003 in multiple myeloma (MM), sponsored by Fortvita Biologics. Started Sep 2026; status: recruiting.
02
Drugs
IBI3003
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07336472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07336472.